Evidence map›Paper›PMID 36581339›Full record

ArticleCancer genomics & proteomics

Evaluating the Impacts of CYP3A4*1B and CYP3A5*3 Variations on Pharmacokinetic Behavior and Clinical Outcomes in Multiple Myeloma Patients With Autologous Stem Cell Transplant.

Junan Li, Yu Kyoung Cho, Douglas W Sborov, Mitch A Phelps, Craig C Hofmeister, Ming J Poi

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer genomics & proteomics. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 67% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 1 country.

Junan LiDivision of Pharmacy Practice and Science, College of Pharmacy, The Ohio State University, Columbus, OH, U.S.A.; li.225@osu.edu poi.2@osu.edu.
Yu Kyoung ChoDivision of Pharmaceutics and Pharmacology, College of Pharmacy, The Ohio State University, Columbus, OH, U.S.A.
Douglas W SborovDivision of Hematology and Hematologic Malignancies, University of Utah-Huntsman Cancer Institute, Salt Lake City, UT, U.S.A.
Mitch A PhelpsComprehensive Cancer Center, The Ohio State University, Columbus, OH, U.S.A.
Craig C HofmeisterDepartment of Hematology & Oncology, Winship Cancer Institute of Emory University, Atlanta, GA, U.S.A.
Ming J PoiDivision of Pharmacy Practice and Science, College of Pharmacy, The Ohio State University, Columbus, OH, U.S.A.; li.225@osu.edu poi.2@osu.edu.
The Ohio State University · USEmory University · USHuntsman Cancer Institute · USThe Ohio State University Wexner Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

aimThere exists considerably large interpatient variability in pharmacokinetic exposure of high dose melphalan in multiple myeloma patients with hematopoietic stem-cell transplantation. In this study, we aimed to evaluate the potential impacts of CYP3A4*1B (rs2940574) and CYP3A5*3 (rs776746) variations on pharmacokinetic properties of melphalan and clinical outcomes in multiple myeloma (MM) patients. PATIENTS AND

methodsGenotypes of CYP3A4*1B (rs2940574) and CYP3A5*3 (rs776746) were determined by validated gene-specific real-time PCR (RT-PCR) assays using DNA samples from 108 MM patients; plasma concentrations of melphalan at different time points were quantified using liquid chromatography-tandem mass spectrometry (LC-MS/MS).

resultsCYP3A4*1B/*1B and CYP3A5*3/*3 carriers appeared to have a short median progression-free survival time and a higher maximum melphalan plasma concentration than non-carriers [792 vs. over 950 days, p=0.08; 9.91 (2.67, 34.03) vs. 8.66 (4.46, 17.61) mg/l, p=0.039].

conclusionCYP3A4*1B/*1B and CYP3A5*3/*3 variations might influence melphalan therapy in MM patients through yet-to-be-identified mechanisms.

Indexed as

Cytochrome P-450 CYP3AMultiple MyelomaChromatography, LiquidGenotypeHumansMelphalanStem Cell TransplantationTandem Mass SpectrometryCYP3A4 protein, humanCYP3A5 protein, humanCytochrome P-450 CYP3AMelphalanCYP3A4*1BCYP3A5*3melphalanMultiple myelomapharmacokinetics

Identifiers

PMID36581339
PMCPMC9806672
OpenAlexW4313424072

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.